{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:37:57Z","timestamp":1790257077697,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Overproduction or poor clearance of amyloids lead to amyloid aggregation and even amyloidosis development. Different amyloids may interact synergistically to promote their aggregation and accelerate pathology in amyloidoses. Amyloid oligomers assembled from different amyloids share common structures and epitopes, and are considered the most toxic species in the pathologic processes of amyloidoses, which suggests that an agent targeting the common epitope of toxic oligomers could provide benefit to several amyloidoses. In this study, we firstly showed that an oligomer-specific single-chain variable fragment antibody, W20 simultaneously improved motor and cognitive function in Parkinson\u2019s disease and Huntington\u2019s disease mouse models, and attenuated a number of neuropathological features by reducing \u03b1-synuclein and mutant huntingtin protein aggregate load and preventing synaptic degeneration. Neuroinflammation and oxidative stress<jats:italic>in vivo<\/jats:italic>were also markedly inhibited. The proposed strategy targeting the common epitopes of amyloid oligomers presents promising potential for treating Parkinson\u2019s disease, Huntington\u2019s disease, Alzheimer\u2019s disease, and other amyloidoses.<\/jats:p>","DOI":"10.1038\/srep36631","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T13:07:03Z","timestamp":1478610423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses"],"prefix":"10.1038","volume":"6","author":[{"given":"Jun","family":"Zha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"BFsrep36631_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/156720510790274437","volume":"7","author":"E Zerovnik","year":"2010","unstructured":"Zerovnik, E. Protein conformational pathology in Alzheimer\u2019s and other neurodegenerative diseases; new targets for therapy. Current Alzheimer research 7, 74\u201383 (2010).","journal-title":"Current Alzheimer research"},{"key":"BFsrep36631_CR2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.22615","volume":"70","author":"M Jucker","year":"2011","unstructured":"Jucker, M. & Walker, L. C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Annals of neurology 70, 532\u2013540 (2011).","journal-title":"Annals of neurology"},{"key":"BFsrep36631_CR3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1084\/jem.20150656","volume":"212","author":"TJ Montine","year":"2015","unstructured":"Montine, T. J. & Montine, K. S. Precision medicine: Clarity for the clinical and biological complexity of Alzheimer\u2019s and Parkinson\u2019s diseases. The Journal of experimental medicine 212, 601\u2013605 (2015).","journal-title":"The Journal of experimental medicine"},{"key":"BFsrep36631_CR4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","volume":"75","author":"F Chiti","year":"2006","unstructured":"Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annual review of biochemistry 75, 333\u2013366 (2006).","journal-title":"Annual review of biochemistry"},{"key":"BFsrep36631_CR5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/brain\/awn349","volume":"132","author":"KE Paleologou","year":"2009","unstructured":"Paleologou, K. E. et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain: a journal of neurology 132, 1093\u20131101 (2009).","journal-title":"Brain: a journal of neurology"},{"key":"BFsrep36631_CR6","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","volume":"75","author":"T Tokuda","year":"2010","unstructured":"Tokuda, T. et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766\u20131772 (2010).","journal-title":"Neurology"},{"key":"BFsrep36631_CR7","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.3233\/JAD-2012-129001","volume":"33","author":"R Kayed","year":"2013","unstructured":"Kayed, R. & Lasagna-Reeves, C. A. Molecular mechanisms of amyloid oligomers toxicity. Journal of Alzheimer\u2019s disease: JAD 33 Suppl 1, S67\u2013S78 (2013).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"BFsrep36631_CR8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bcp.2013.12.023","volume":"88","author":"MJ Guerrero-Munoz","year":"2014","unstructured":"Guerrero-Munoz, M. J., Castillo-Carranza, D. L. & Kayed, R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochemical pharmacology 88, 468\u2013478 (2014).","journal-title":"Biochemical pharmacology"},{"key":"BFsrep36631_CR9","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.bbamem.2015.01.018","volume":"1848","author":"M Andreasen","year":"2015","unstructured":"Andreasen, M., Lorenzen, N. & Otzen, D. Interactions between misfolded protein oligomers and membranes: A central topic in neurodegenerative diseases? Biochimica et biophysica acta 1848, 1897\u20131907 (2015).","journal-title":"Biochimica et biophysica acta"},{"key":"BFsrep36631_CR10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jmb.2012.01.006","volume":"421","author":"M Fandrich","year":"2012","unstructured":"Fandrich, M. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. Journal of molecular biology 421, 427\u2013440 (2012).","journal-title":"Journal of molecular biology"},{"key":"BFsrep36631_CR11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1126\/science.1079469","volume":"300","author":"R Kayed","year":"2003","unstructured":"Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486\u2013489 (2003).","journal-title":"Science"},{"key":"BFsrep36631_CR12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-2-18","volume":"2","author":"R Kayed","year":"2007","unstructured":"Kayed, R. et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular neurodegeneration 2, 18 (2007).","journal-title":"Molecular neurodegeneration"},{"key":"BFsrep36631_CR13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1582-4934.2011.01507.x","volume":"16","author":"KA Jellinger","year":"2012","unstructured":"Jellinger, K. A. Interaction between pathogenic proteins in neurodegenerative disorders. Journal of cellular and molecular medicine 16, 1166\u20131183 (2012).","journal-title":"Journal of cellular and molecular medicine"},{"key":"BFsrep36631_CR14","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q. & LaFerla, F. M. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. The Journal of neuroscience: the official journal of the Society for Neuroscience 30, 7281\u20137289 (2010).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"BFsrep36631_CR15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23956","volume":"74","author":"K Jackson","year":"2013","unstructured":"Jackson, K., Barisone, G. A., Diaz, E., Jin, L. W., DeCarli, C. & Despa, F. Amylin deposition in the brain: A second amyloid in Alzheimer disease? Annals of neurology 74, 517\u2013526 (2013).","journal-title":"Annals of neurology"},{"key":"BFsrep36631_CR16","doi-asserted-by":"crossref","first-page":"17490","DOI":"10.1074\/jbc.M311300200","volume":"279","author":"B O\u2019Nuallain","year":"2004","unstructured":"O\u2019Nuallain, B., Williams, A. D., Westermark, P. & Wetzel, R. Seeding specificity in amyloid growth induced by heterologous fibrils. The Journal of biological chemistry 279, 17490\u201317499 (2004).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep36631_CR17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton, R. L. Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain pathology 10, 378\u2013384 (2000).","journal-title":"Brain pathology"},{"key":"BFsrep36631_CR18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s004010000271","volume":"101","author":"I Ferrer","year":"2001","unstructured":"Ferrer, I. et al. Prion protein expression in senile plaques in Alzheimer\u2019s disease. Acta neuropathologica 101, 49\u201356 (2001).","journal-title":"Acta neuropathologica"},{"key":"BFsrep36631_CR19","first-page":"147","volume":"4","author":"AC Wilson","year":"2011","unstructured":"Wilson, A. C., Dugger, B. N., Dickson, D. W. & Wang, D. S. TDP-43 in aging and Alzheimer\u2019s disease - a review. International journal of clinical and experimental pathology 4, 147\u2013155 (2011).","journal-title":"International journal of clinical and experimental pathology"},{"key":"BFsrep36631_CR20","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1096\/fj.11-199851","volume":"26","author":"CA Lasagna-Reeves","year":"2012","unstructured":"Lasagna-Reeves, C. A. et al. Identification of oligomers at early stages of tau aggregation in Alzheimer\u2019s disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 26, 1946\u20131959 (2012).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"BFsrep36631_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00401-013-1157-y","volume":"126","author":"GG Kovacs","year":"2013","unstructured":"Kovacs, G. G. et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta neuropathologica 126, 365\u2013384 (2013).","journal-title":"Acta neuropathologica"},{"key":"BFsrep36631_CR22","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1172\/JCI29178","volume":"116","author":"JM Savitt","year":"2006","unstructured":"Savitt, J. M., Dawson, V. L. & Dawson, T. M. Diagnosis and treatment of Parkinson disease: molecules to medicine. The Journal of clinical investigation 116, 1744\u20131754 (2006).","journal-title":"The Journal of clinical investigation"},{"key":"BFsrep36631_CR23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm.3514","volume":"20","author":"N Wang","year":"2014","unstructured":"Wang, N. et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington\u2019s disease. Nature medicine 20, 536\u2013541 (2014).","journal-title":"Nature medicine"},{"key":"BFsrep36631_CR24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jnc.12305","volume":"126","author":"S Rasool","year":"2013","unstructured":"Rasool, S., Martinez-Coria, H., Wu, J. W., LaFerla, F. & Glabe, C. G. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Abeta deposition and tau pathology in 3xTg-AD mice. Journal of neurochemistry 126, 473\u2013482 (2013).","journal-title":"Journal of neurochemistry"},{"key":"BFsrep36631_CR25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/JAD-122419","volume":"35","author":"C Xiao","year":"2013","unstructured":"Xiao, C. et al. Brain transit and ameliorative effects of intranasally delivered anti-amyloid-beta oligomer antibody in 5XFAD mice. Journal of Alzheimer\u2019s disease: JAD 35, 777\u2013788 (2013).","journal-title":"Journal of Alzheimer\u2019s disease: JAD"},{"key":"BFsrep36631_CR26","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.bbapap.2011.09.005","volume":"1814","author":"X Zhang","year":"2011","unstructured":"Zhang, X. et al. Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses. Biochimica et biophysica acta 1814, 1703\u20131712 (2011).","journal-title":"Biochimica et biophysica acta"},{"key":"BFsrep36631_CR27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.febslet.2008.12.064","volume":"583","author":"XP Wang","year":"2009","unstructured":"Wang, X. P. et al. Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS letters 583, 579\u2013584 (2009).","journal-title":"FEBS letters"},{"key":"BFsrep36631_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/15672050113106660176","volume":"11","author":"M Zhao","year":"2014","unstructured":"Zhao, M. et al. Pan-amyloid oligomer specific scFv antibody attenuates memory deficits and brain amyloid burden in mice with Alzheimer\u2019s disease. Current Alzheimer research 11, 69\u201378 (2014).","journal-title":"Current Alzheimer research"},{"key":"BFsrep36631_CR29","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1073\/pnas.132197599","volume":"99","author":"MK Lee","year":"2002","unstructured":"Lee, M. K. et al. Human alpha-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53 \u2013&gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 99, 8968\u20138973 (2002).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep36631_CR30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.nbd.2005.08.005","volume":"21","author":"EL Unger","year":"2006","unstructured":"Unger, E. L. et al. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiology of disease 21, 431\u2013443 (2006).","journal-title":"Neurobiology of disease"},{"key":"BFsrep36631_CR31","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jnr.22331","volume":"88","author":"DR Graham","year":"2010","unstructured":"Graham, D. R. & Sidhu, A. Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. Journal of neuroscience research 88, 1777\u20131783 (2010).","journal-title":"Journal of neuroscience research"},{"key":"BFsrep36631_CR32","doi-asserted-by":"crossref","first-page":"e89076","DOI":"10.1371\/journal.pone.0089076","volume":"9","author":"S Arawaka","year":"2014","unstructured":"Arawaka, S. et al. Zonisamide attenuates alpha-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson\u2019s disease. PloS one 9, e89076 (2014).","journal-title":"PloS one"},{"key":"BFsrep36631_CR33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-6147(93)90029-J","volume":"14","author":"B Giros","year":"1993","unstructured":"Giros, B. & Caron, M. G. Molecular characterization of the dopamine transporter. Trends in pharmacological sciences 14, 43\u201349 (1993).","journal-title":"Trends in pharmacological sciences"},{"key":"BFsrep36631_CR34","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/hmg\/ddq086","volume":"19","author":"WW Smith","year":"2010","unstructured":"Smith, W. W. et al. Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model. Human molecular genetics 19, 2087\u20132098 (2010).","journal-title":"Human molecular genetics"},{"key":"BFsrep36631_CR35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/039463200902200405","volume":"22","author":"H Wilms","year":"2009","unstructured":"Wilms, H. et al. Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. International journal of immunopathology and pharmacology 22, 897\u2013909 (2009).","journal-title":"International journal of immunopathology and pharmacology"},{"key":"BFsrep36631_CR36","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray, M. et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 28, 6182\u20136195 (2008).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"BFsrep36631_CR37","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/dds037","volume":"21","author":"MA Pouladi","year":"2012","unstructured":"Pouladi, M. A. et al. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Human molecular genetics 21, 2219\u20132232 (2012).","journal-title":"Human molecular genetics"},{"key":"BFsrep36631_CR38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2014.08.021","volume":"73","author":"JG Doria","year":"2015","unstructured":"Doria, J. G. et al. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington\u2019s disease. Neurobiology of disease 73, 163\u2013173 (2015).","journal-title":"Neurobiology of disease"},{"key":"BFsrep36631_CR39","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","volume":"33","author":"DA Simmons","year":"2013","unstructured":"Simmons, D. A. et al. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington\u2019s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 33, 18712\u201318727 (2013).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"BFsrep36631_CR40","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","volume":"32","author":"J Bouchard","year":"2012","unstructured":"Bouchard, J. et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 32, 18259\u201318268 (2012).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"BFsrep36631_CR41","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/jcbfm.2014.110","volume":"34","author":"L Boussicault","year":"2014","unstructured":"Boussicault, L. et al. Impaired brain energy metabolism in the BACHD mouse model of Huntington\u2019s disease: critical role of astrocyte-neuron interactions. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 34, 1500\u20131510 (2014).","journal-title":"Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"key":"BFsrep36631_CR42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/imt.13.162","volume":"6","author":"V Lindstrom","year":"2014","unstructured":"Lindstrom, V. et al. Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson\u2019s disease and other Lewy body disorders. Immunotherapy 6, 141\u2013153 (2014).","journal-title":"Immunotherapy"},{"key":"BFsrep36631_CR43","doi-asserted-by":"crossref","first-page":"10253","DOI":"10.1523\/JNEUROSCI.0581-12.2012","volume":"32","author":"ME Larson","year":"2012","unstructured":"Larson, M. E. et al. Soluble alpha-synuclein is a novel modulator of Alzheimer\u2019s disease pathophysiology. The Journal of neuroscience: the official journal of the Society for Neuroscience 32, 10253\u201310266 (2012).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"BFsrep36631_CR44","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato, C., Valenza, M. & Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiological reviews 90, 905\u2013981 (2010).","journal-title":"Physiological reviews"},{"key":"BFsrep36631_CR45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1937-6448(08)01406-8","volume":"270","author":"A Surguchov","year":"2008","unstructured":"Surguchov, A. Molecular and cellular biology of synucleins. International review of cell and molecular biology 270, 225\u2013317 (2008).","journal-title":"International review of cell and molecular biology"},{"key":"BFsrep36631_CR46","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/mds.22207","volume":"23","author":"GG Kovacs","year":"2008","unstructured":"Kovacs, G. G., Milenkovic, I. J., Preusser, M. & Budka, H. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Movement disorders: official journal of the Movement Disorder Society 23, 1608\u20131612 (2008).","journal-title":"Movement disorders: official journal of the Movement Disorder Society"},{"key":"BFsrep36631_CR47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0070-2153(06)76003-3","volume":"76","author":"A Williams","year":"2006","unstructured":"Williams, A. et al. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Current topics in developmental biology 76, 89\u2013101 (2006).","journal-title":"Current topics in developmental biology"},{"key":"BFsrep36631_CR48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainresbull.2006.10.029","volume":"72","author":"YF Tai","year":"2007","unstructured":"Tai, Y. F. et al. Imaging microglial activation in Huntington\u2019s disease. Brain research bulletin 72, 148\u2013151 (2007).","journal-title":"Brain research bulletin"},{"key":"BFsrep36631_CR49","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","volume":"22","author":"HY Hsiao","year":"2013","unstructured":"Hsiao, H. Y., Chen, Y. C., Chen, H. M., Tu, P. H. & Chern, Y. A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington\u2019s disease. Human molecular genetics 22, 1826\u20131842 (2013).","journal-title":"Human molecular genetics"},{"key":"BFsrep36631_CR50","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman, S. et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553\u20131562 (2005).","journal-title":"Neurology"},{"key":"BFsrep36631_CR51","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1172\/JCI64484","volume":"122","author":"W Kwan","year":"2012","unstructured":"Kwan, W. et al. Mutant huntingtin impairs immune cell migration in Huntington disease. The Journal of clinical investigation 122, 4737\u20134747 (2012).","journal-title":"The Journal of clinical investigation"},{"key":"BFsrep36631_CR52","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/hmg\/dds516","volume":"22","author":"A Valencia","year":"2013","unstructured":"Valencia, A. et al. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington\u2019s disease. Human molecular genetics 22, 1112\u20131131 (2013).","journal-title":"Human molecular genetics"},{"key":"BFsrep36631_CR53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jnr.21881","volume":"87","author":"J Illuzzi","year":"2009","unstructured":"Illuzzi, J., Yerkes, S., Parekh-Olmedo, H. & Kmiec, E. B. DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates. Journal of neuroscience research 87, 733\u2013747 (2009).","journal-title":"Journal of neuroscience research"},{"key":"BFsrep36631_CR54","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.nbd.2012.03.013","volume":"46","author":"D Xue","year":"2012","unstructured":"Xue, D. et al. A multifunctional peptide rescues memory deficits in Alzheimer\u2019s disease transgenic mice by inhibiting Abeta42-induced cytotoxicity and increasing microglial phagocytosis. Neurobiology of disease 46, 701\u2013709 (2012).","journal-title":"Neurobiology of disease"},{"key":"BFsrep36631_CR55","doi-asserted-by":"crossref","first-page":"e54200","DOI":"10.1371\/journal.pone.0054200","volume":"8","author":"CA Lieu","year":"2013","unstructured":"Lieu, C. A., Chinta, S. J., Rane, A. & Andersen, J. K. Age-related behavioral phenotype of an astrocytic monoamine oxidase-B transgenic mouse model of Parkinson\u2019s disease. PloS one 8, e54200 (2013).","journal-title":"PloS one"},{"key":"BFsrep36631_CR56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbr.2014.02.002","volume":"264","author":"PX Xu","year":"2014","unstructured":"Xu, P. X. et al. Rutin improves spatial memory in Alzheimer\u2019s disease transgenic mice by reducing Abeta oligomer level and attenuating oxidative stress and neuroinflammation. Behav Brain Res 264, 173\u2013180 (2014).","journal-title":"Behav Brain Res"},{"key":"BFsrep36631_CR57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/hmg\/dds397","volume":"22","author":"AL Southwell","year":"2013","unstructured":"Southwell, A. L. et al. A fully humanized transgenic mouse model of Huntington disease. Human molecular genetics 22, 18\u201334 (2013).","journal-title":"Human molecular genetics"},{"key":"BFsrep36631_CR58","doi-asserted-by":"crossref","first-page":"e12075","DOI":"10.1371\/journal.pone.0012075","volume":"5","author":"S Lu","year":"2010","unstructured":"Lu, S. et al. Targeting of embryonic stem cells by peptide-conjugated quantum dots. PloS one 5, e12075 (2010).","journal-title":"PloS one"},{"key":"BFsrep36631_CR59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.freeradbiomed.2014.06.013","volume":"74","author":"WW Zhou","year":"2014","unstructured":"Zhou, W. W. et al. Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease. Free radical biology & medicine 74, 50\u201363 (2014).","journal-title":"Free radical biology & medicine"},{"key":"BFsrep36631_CR60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0065-3233(03)66002-X","volume":"66","author":"JW Ponder","year":"2003","unstructured":"Ponder, J. W. & Case, D. A. Force fields for protein simulations. Advances in protein chemistry 66, 27\u201385 (2003).","journal-title":"Advances in protein chemistry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep36631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36631","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T12:42:02Z","timestamp":1718887322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep36631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep36631"],"URL":"https:\/\/doi.org\/10.1038\/srep36631","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]},"assertion":[{"value":"29 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36631"}}